Tag: dabigatran
Dabigatran consistently shown to decrease risk of brain bleeds compared to...
A new comparative study between dabigatran and warfarin finds similar ischemic stroke risks, but fewer brain bleeds for dabigatron compared with warfarin in US-based...
EMA issues positive opinion for updated dabigatran summary of characteristics
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for an update to...
RE-CIRCUIT data to be included in European summary of product characteristics...
The committee for medicinal products for human use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for an update to...
ESC 2017: Case builds for dropping aspirin from triple therapy in...
The RE-DUAL PCI trial indicates that dual therapy with the non-vitamin K antagonist oral anticoagulant dabigatran (Pradaxa, Boehringer Ingelheim)—and not aspirin—and a P2Y12 inhibitor...
ACC 2017: Uninterrupted dabigatran performs better than warfarin in atrial fibrillation...
Results from the RE-CIRCUIT study have shown that uninterrupted dabigatran (Pradaxa, Boehringer Ingelheim), was associated with fewer bleeding complications than uninterrupted warfarin before, during...
Patient enrolment complete in study assessing use of dabigatran atrial fibrillation...
Patient enrolment into the international Phase IIIb RE-DUAL PCI study is complete. The study is evaluating the safety and efficacy of dabigatran (Pradaxa, Boehringer...
Boehringer Ingelheim launches RE-VECTO global programme to explore idarucizumab use in...
Boehringer Ingelheim has announced the launch of its global RE-VECTO programme for idarucizumab (Praxbind), the specific reversal agent for dabigatran etexilate (Pradaxa).
Idarucizumab is approved...
Idarucizumab licensed in Europe as specific reversal agent of dabigatran
Boehringer Ingelheim has announced that the European Commission has licensed idarucizumab (Praxbind) for rapid and specific reversal of the anticoagulant effects of dabigatran etexilate in cases of emergency surgery/urgent procedures or in situations of life-threatening or uncontrolled bleeding.